About: European Commission–AstraZeneca COVID-19 vaccine dispute     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : owl:Thing, within Data Space : dbpedia.org associated with source document(s)
QRcode icon
http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FEuropean_Commission%E2%80%93AstraZeneca_COVID-19_vaccine_dispute

A dispute broke out in January 2021 between the European Commission and the pharmaceutical company AstraZeneca AB about the provision of COVID-19 vaccines during the COVID-19 pandemic, and, in February, spilled out into a dispute over Article 16 of the Northern Ireland Protocol. Vaccination proceeded apace in the UK but more slowly in the EU, and by the end of March 2021, over 30% of the UK population had received at least one dose of vaccine compared to about 8% of the EU population. This was partly due to limited availability of the AstraZeneca vaccine in the EU. The World Health Organization and the European Medicines Agency continued to state that the vaccine was safe and effective. However, a representative of the European Medicines Agency said in June that vaccines based on the mRNA

AttributesValues
rdfs:label
  • الجدل حول لقاح كوفيد-19 بين شركة أسترازينكا والمفوضية الأوروبية (ar)
  • European Commission–AstraZeneca COVID-19 vaccine dispute (en)
rdfs:comment
  • نشب نزاع بين المفوضية الأوروبية وشركة أسترازينكا إيه بي للأدوية في يناير عام 2021 يتعلق بتوفير لقاحات كوفيد-19 خلال الجائحة، وامتد إلى نزاع حول المادة رقم 16 من بروتوكول (ميثاق) إيرلندا الشمالية. استمر التلقيح بخطى سريعة في المملكة المتحدة ولكن بشكل أبطأ منه في الاتحاد الأوروبي، وكان 30% من سكان بريطانيا قد تلقوا على الأقل الجرعة الأولى من اللقاح بحلول نهاية مارس 2021 مقارنة بنحو 8% من سكان الاتحاد الأوروبي. يعود سبب ذلك جزئيًا إلى التوافر المحدود للقاح أسترازينكا في الاتحاد الأوروبي. استمرت منظمة الصحة العالمية ووكالة الأدوية الأوروبية بالتصريح أن اللقاح كان آمنًا وفعالًا. من ناحية ثانية، قال ممثل وكالة الأدوية الأوروبية في يونيو أنه يجب تفضيل اللقاحات المعتمدة على تقنية إم-رنا في حال توفرها لجميع الفئات العمرية، بما في ذلك لمن أعمارهم تتعدى الستين عامًا. (ar)
  • A dispute broke out in January 2021 between the European Commission and the pharmaceutical company AstraZeneca AB about the provision of COVID-19 vaccines during the COVID-19 pandemic, and, in February, spilled out into a dispute over Article 16 of the Northern Ireland Protocol. Vaccination proceeded apace in the UK but more slowly in the EU, and by the end of March 2021, over 30% of the UK population had received at least one dose of vaccine compared to about 8% of the EU population. This was partly due to limited availability of the AstraZeneca vaccine in the EU. The World Health Organization and the European Medicines Agency continued to state that the vaccine was safe and effective. However, a representative of the European Medicines Agency said in June that vaccines based on the mRNA (en)
foaf:depiction
  • http://commons.wikimedia.org/wiki/Special:FilePath/Oxford_AstraZeneca_COVID-19_vaccine_(2021)_I_(cropped).jpg
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
Link from a Wikipage to an external page
sameAs
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (61 GB total memory, 51 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software